Technology
TeraMedica announced a Partner Agreement with Frontier Solutions Group. FrontierSG now offers complete VNA solutions including integrated storage products from IBM and TeraMedica’s Evercore Clinical Enterprise Suite, the leading vendor neutral archive (VNA) in the industry.
March 26, 2013
News
In addition to improving life quality and diminishing pain, total hip replacement (THR) is associated with reduced mortality, heart failure, depression and diabetes rates in Medicare patients with osteoarthritis, according to a new study presented at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS). The procedure also is cost effective with the seven-year costs of THR only $6,366 higher than the cost of treating an osteoarthritis patient for hip pain without THR.
March 25, 2013
News
The American Society of Echocardiography (ASE) released a list of five interventions whose appropriateness physicians and patients should discuss as part of Choosing Wisely, an initiative of the ABIM Foundation, along with Consumer Reports. Third in the list, they ask that patients and their doctors talk about the real need for an echocardiogram when preparing for a surgery.
March 25, 2013Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News
March 25, 2013 — W. L. Gore & Associates introduced its Gore DrySeal Sheath with hydrophilic coating in Europe.
March 25, 2013Feature
March 25, 2013 — The largest randomized study of the vitamin niacin in patients with occlusive arterial disease (narrowing of the arteries) has shown a significant increase in adverse side effects when it is combined with statin treatment. Results from the HPS2-THRIVE study, including the reasons patients stopped the study treatment, were published online.
March 25, 2013
McKesson highlighted enhancements to its cardiovascular information system (CVIS) version 13. The system offers new ...
March 22, 2013Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024News
The Medical Imaging and Technology Alliance (MITA), Advanced Medical Technology Association (AdvaMed) and the Medical Device Manufacturers Association (MDMA) applauded the adoption of an amendment to the Fiscal Year 2014 Senate Budget Resolution that expresses support for repeal of the medical device tax.
March 22, 2013News
A new report that breast cancer patients treated with low doses of radiation therapy have a heightened risk of heart disease suggests that physicians need to work with patients before, during, and after treatment to minimize that risk, according to an accompanying editorial in the March 14 issue of the New England Journal of Medicine.
March 22, 2013
Technology
GE Healthcare announced the U.S. Food and Drug Administration (FDA) approval of a new indication for AdreView (Iobenguane I 123 Injection), the first and only FDA approved molecular imaging agent to link nerve function in the heart to a patient’s mortality risk.[1] AdreView is approved for the scintigraphic assessment of myocardial sympathetic innervation (cardiac nerve activity) to assist in the evaluation of patients with New York Heart Association (NYHA) Class II or Class III heart failure and left ventricular ejection fraction (LVEF) ? 35 percent.[2]
March 22, 2013Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
Feature
Abbott announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of treatment with the MitraClip device outweigh its risks in patients with significant symptomatic mitral regurgitation (MR) who have been determined by a cardiac surgeon to be too high risk for open mitral valve surgery and in whom existing co-morbidities would not preclude the expected benefit from correction of the MR.
March 22, 2013
News
Network security issues, vital infrastructure upgrades, electronic health record (EHR) implementation and impending federal deadlines will guide priorities this year, according to an independent research study of 100 healthcare provider CIOs and senior IT executives that was commissioned by Level 3 Communications Inc.
March 22, 2013Technology
Guerbet announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine), a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
March 22, 2013Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
Feature
The American College of Cardiology (ACC) and Heart Rhythm Society (HRS), along with key specialty societies, released appropriate use criteria for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices.
March 21, 2013News
Cordis Corp. announced it has completed the acquisition of Flexible Stenting Solutions Inc., whose technology provides Cordis with the opportunity to evolve the S.M.A.R.T. stent platform to address unmet needs in the treatment of peripheral artery disease (PAD).
March 21, 2013News
Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) study at Middelheim Hospital in Antwerp, Belgium. DIRECT II is a prospective, randomized, multi-center clinical study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to Medtronic’s Resolute Integrity drug-eluting stent. The study builds on the positive 6-month results of the DIRECT I first-in-man study which evaluated the Svelte drug-eluting coronary stent IDS in 30 patients in New Zealand. In DIRECT I, the Svelte drug-eluting coronary stent IDS met all study endpoints and demonstrated in-stent neointimal volume obstruction of 2.7 percent as assessed by intravascular ultrasound (IVUS), which is one-third to one-half the volumetric obstruction observed in market-leading drug-eluting stent first-in-man studies.
March 20, 2013© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now